Atopic dermatitis is a chronic skin condition marked by itchy, inflamed patches that flare and fade over time. It affects about 10% of adults and 25% of children in the U.S. Treatment has expanded beyond topical steroids to include JAK inhibitors, monoclonal antibodies, and newer creams that target specific immune pathways.
What's actually going on in research
Trials are testing oral JAK inhibitors that work systemically, monoclonal antibodies targeting different immune signals, topical drugs that block inflammation without steroid side effects, and microbiome treatments that address skin bacteria. Researchers are also studying why some people develop food allergies alongside eczema and testing treatments to prevent that progression.
JAK inhibitors
Several JAK inhibitors are now FDA-approved for atopic dermatitis, including upadacitinib and abrocitinib as pills. Trials continue testing newer JAK inhibitors and combinations to see if they can achieve clear skin with fewer side effects.
Biologics targeting IL-13 and IL-4
Dupilumab blocks IL-4 and IL-13 signals that drive inflammation and is now widely used for moderate-to-severe disease. Newer biologics targeting these pathways are in trials, aiming for stronger effects or less frequent dosing.
Microbiome treatments
Topical bacteria sprays and creams aim to restore healthy skin bacteria that people with eczema often lack. Early trials suggest this approach may reduce flares and need for steroids.
What to know before you search
Eligibility typically depends on disease severity measured by body surface area affected, itch intensity, prior treatment response, and whether topical steroids have been tried.
What types of trials are currently open
- Treatment trials — Testing new pills, injections, or creams to control inflammation and itching. Many compare new drugs to dupilumab or topical steroids.
- Prevention trials — Testing whether moisturizers or immune-modulating treatments applied early in infancy can prevent eczema or food allergies from developing.
- Topical trials — Testing creams and ointments that block inflammation through non-steroid mechanisms, often with fewer long-term skin changes.
- Microbiome trials — Testing bacterial sprays, probiotics, or prebiotics to restore healthy skin bacteria and reduce flares.
- Combination trials — Testing whether combining a biologic or JAK inhibitor with another treatment leads to clearer skin than either alone.
Recently added Atopic Dermatitis trials
The LITTLE OWLS Study (in German: "Kleine Eulen OWL"): Exploring the Early-life Microbiome Development and Physical and Mental Health Outcomes During Childhood.
The LITTLE OWLS study is a prospective, longitudinal birth cohort study investigating early-life microbiome development and its association with physical and mental health outcomes during childhood. Recruitment began in 2024, enrolling families from late pregnancy through the child's first 6 years of life, with a target of at least 1000- 1200 children and their families. The study characterizes longitudinal microbiome trajectories-including resilience and dysbiosis-and their relationship to common chronic diseases. Data are collected via online surveys, symptom and medication diaries, annual clinical exams, and repeated biological sampling of the child, mother, father/partner, siblings, and household environment. Findings are intended to support future diagnostics, prevention, and therapy for common chronic physical and mental diseases.
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis. Approximately 415 participants will be randomized in a 2:1 ratio to receive roflumilast cream 0.3% or matching vehicle cream during a 4-week double-blind, vehicle-controlled treatment period. Following completion of the double-blind treatment period, all participants will enter a 48-week open-label extension and receive roflumilast cream 0.3%. The study will assess the efficacy of roflumilast cream 0.3% in improving signs and symptoms of atopic dermatitis and evaluate its long-term safety and tolerability through Week 52.
Find Atopic Dermatitis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.